Hyperpigmentation following sclerotherapy for varicose veins Skin and Connective Tissue Diseases Hyperpigmentation following sclerotherapy for varicose veins
Conditions
Interventions
Participants who were included with telangiectasia, reticular or varicose veins who were candidates for sclerotherapy. They received Sclerotherapy using polidocanol 1% as sclerosant agent, 10ml maximu
Sponsors
CLINEDEM
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years 2. Telangiectatic, reticular, or varicose veins in lower limbs 3. Candidate for sclerotherapy 4. BMI 20 to 40 kg/m2 5. Fitzpatrick skin tone I – V 6. Signed consent to participate
Exclusion criteria
Exclusion criteria: 1. Acute thrombosis 2. History of deep vein thrombosis 3. Deep vein reflux 4. Saphenous vein reflux 5. Pregnancy 6. Bed confinement 7. Long term use of steroidal or nonsteroidal anti-inflammatory drugs (such as corticoids, methotrexate, etc.) 8. Severe leg edema
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Incidence of post sclerotherapy hyperpigmentation measured using computer software at baseline, 1 and 3 months 2. Total area of hyperpigmentation measured using computer software at baseline, 1 and 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Presence of major bleeding measured using computer software at baseline, 1 and 3 months 2. Clinical response of vein disappearance measured using computer software at baseline, 1 and 3 months | — |
Countries
Mexico
Outcome results
None listed